| Hazard Information | Back Directory | [Uses]
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer[1][2]. | [Definition]
ChEBI: Elpamotide is an oligopeptide. | [IC 50]
VEGFR2 | [References]
[1] Yamaue H, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci. 2015 Jul;106(7):883-90. DOI:10.1111/cas.12674
[2] Wada S, et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46. DOI:10.1158/0008-5472.CAN-04-3759 |
|
| Company Name: |
YantaiBio
|
| Tel: |
13758194781 15083780366 |
| Website: |
|
|